Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major metastatic prostate cancer markets are expected to exhibit a CAGR of 6.22% during 2024-2034.

The metastatic prostate cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic prostate cancer, also known as advanced or stage IV prostate cancer, is a form of neoplasm that originates in the prostate gland and spreads to other parts of the body. This condition occurs when cancerous cells break away from the primary tumor in the prostate and travel through the bloodstream or lymphatic system to different organs or tissues, where they form secondary tumors. Some common sites of metastasis associated with the disease include the bones, lymph nodes, liver, lungs, and other distant organs. Individuals suffering from this ailment may experience increased frequency of urination, bone pain, a general sense of tiredness or weakness, loss of appetite, swelling, erectile dysfunction, weakness, numbness, problems with coordination, etc. The diagnosis of metastatic prostate cancer typically involves a review of the patient's clinical features, medical history, and a physical test, including a digital rectal exam. Various diagnostic studies, like positron emission tomography scans, bone scans, magnetic resonance imaging, etc., are also utilized to evaluate the extent of cancer and detect metastasis.

The increasing cases of genetic mutations that impair the cell's ability to repair DNA damage, which can result in the accumulation of additional variations and genomic instability, are primarily driving the metastatic prostate cancer market. Besides this, the rising incidences of hormonal imbalances, including elevated testosterone levels that can lead to overactivation of the androgen receptor, causing the tumor to grow abnormally, are creating a positive outlook for the market. Moreover, the widespread adoption of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, to stimulate the body's defense mechanism against cancerous cells is further bolstering the market growth. Apart from this, the escalating application of androgen deprivation therapy, since it aims to suppress the production or block the action of male hormones that enhance the proliferation of tumors among patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiosensitizing agents, which help to make the treatment more potent owing to their numerous benefits, like improved tumor control, reduced toxicity, and synergistic effects with systemic therapies, is expected to drive the metastatic prostate cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metastatic prostate cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic prostate cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic prostate cancer market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the metastatic prostate cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the metastatic prostate cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current metastatic prostate cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the metastatic prostate cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the metastatic prostate cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the metastatic prostate cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of metastatic prostate cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic prostate cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic prostate cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with metastatic prostate cancer across the seven major markets?
What is the size of the metastatic prostate cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of metastatic prostate cancer?
What will be the growth rate of patients across the seven major markets?

Metastatic Prostate Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for metastatic prostate cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic prostate cancer market?
What are the key regulatory events related to the metastatic prostate cancer market?
What is the structure of clinical trial landscape by status related to the metastatic prostate cancer market?
What is the structure of clinical trial landscape by phase related to the metastatic prostate cancer market?
What is the structure of clinical trial landscape by route of administration related to the metastatic prostate cancer market?